Korsana Biosciences, Inc. (KRSA) Key Metrics
KRSA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKRSA returns How much profit the business earns on the capital it uses.
KRSA financial health Debt, liquidity and how easily interest is covered.
KRSA efficiency & capital use Working capital cycle and where the cash goes.
KRSA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KRSA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KRSA cash returned to shareholders
KRSA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $8.89 | $22.54 | $23.45 | $91.87 | $240.80 | $428.40 | $380.80 | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −39.3% | −30.4% | −48.4% | −150.2% | −95.9% | −99.0% | −281.9% | — | — | — |
| Return on invested capital (ROIC) | −68.5% | −61.4% | — | — | — | −102.8% | −310.6% | — | — | — |
| Return on assets (ROA) | −36.1% | −26.6% | −33.5% | −113.9% | −59.1% | −51.5% | −126.9% | — | — | — |
| Return on tangible assets | −35.3% | −31.9% | −39.4% | −243.8% | −87.0% | −67.4% | −66.0% | — | — | — |
| Free cash flow margin | −159.8% | −216.7% | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | — | — | — | — | — | $45.7M | $73.9M | — | — | — |
| Cash & short-term investments | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $54.4M | $97.6M | — | — | — |
| Net debt | −$3.2M | −$3.2M | −$7.6M | −$13.4M | −$54.0M | −$8.7M | −$23.7M | — | — | — |
| Debt / equity | — | — | — | — | — | 0.77 | 0.76 | — | — | — |
| Debt / assets | — | — | — | — | — | 0.40 | 0.40 | — | — | — |
| Current ratio | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 | 3.45 | 5.55 | 0.05 | 0.09 | — |
| Quick ratio | 5.15 | 5.83 | 3.85 | 1.94 | 4.92 | 3.45 | 5.55 | 0.05 | 0.09 | — |
| Working capital | $3.7M | $3.5M | $5.9M | $7.2M | $44.4M | $41.5M | $82.9M | −$17.0M | −$12.8M | — |
| Invested capital | $5.8M | $5.6M | $3.7M | −$2.9M | −$5.7M | $50.8M | $74.1M | −$10.4M | −$8.6M | — |
| Tangible asset value | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M | $59.5M | $97.7M | −$10.4M | −$8.6M | — |
| Net current asset value | $3.7M | $3.5M | $5.9M | $7.2M | $44.4M | $2.6M | $12.4M | −$17.0M | −$12.8M | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $130,000 | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | — | 0.0% | 0.2% | 66.4% | 152.8% | — | — | — |
| Capex / depreciation | — | — | 0.00 | 0.00 | 0.01 | 0.66 | 2.55 | 2.25 | 0.80 | 0.66 |
| Stock-based compensation / revenue | 21.3% | 31.2% | — | — | 289.5% | 653.0% | 435.6% | — | — | — |
| R&D / revenue | 46.2% | 14.3% | — | 2,013.1% | 1,133.6% | 2,457.1% | 2,110.9% | — | — | — |
| SG&A / revenue | 293.5% | 267.1% | — | 4,329.3% | 621.1% | 1,255.1% | 763.3% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 136.9 | 101.5 | — | 120.4 | 12.5 | 127.3 | 119.4 | — | — | — |
| Days payables outstanding | — | — | 578.4 | 157.0 | — | 14.4 | 11.7 | 547.4 | 376.9 | — |
| Cash conversion cycle (days) | — | — | — | -36.5 | — | 112.8 | 107.7 | — | — | — |
| Receivables turnover | 2.67 | 3.60 | — | 3.03 | 29.25 | 2.87 | 3.06 | — | — | — |
| Payables turnover | 0.00 | 0.00 | 0.63 | 2.33 | 0.00 | 25.30 | 31.23 | 0.67 | 0.97 | — |
| Inventory turnover | — | — | — | — | 0.00 | — | — | — | — | — |
| Asset turnover | 0.21 | 0.17 | 0.00 | 0.01 | 0.04 | 0.02 | 0.05 | 0.00 | 0.00 | — |
| Average receivables | $778,000 | $556,000 | — | $98,000 | $113,500 | $800,500 | $1.5M | — | — | — |
| Average payables | $449,000 | $794,000 | $2.1M | $2.4M | $1.5M | $2.2M | $3.0M | $2.3M | $1.8M | — |
| Average inventory | — | — | — | — | $928,000 | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Computed from KRSA's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KRSA valuation and financial ratios
Korsana Biosciences earned a return on equity of −39.3% and a return on invested capital of −68.5% in fiscal 2025. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks.
See the KRSA income statement, the KRSA chart for price history, or the KRSA stock overview for the latest quote and news.
KRSA key metrics FAQ
What is Korsana Biosciences's return on equity?
Korsana Biosciences's return on equity (ROE) was −39.3% in fiscal 2025: net income of -$3.5 million on average shareholders' equity of $9.0 million.
What is Korsana Biosciences's ROIC?
Korsana Biosciences's return on invested capital was −68.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
Does Korsana Biosciences buy back its shares?
Yes. Korsana Biosciences spent $0.1 million on net share repurchases in fiscal 2025.
What is Korsana Biosciences's current ratio?
Korsana Biosciences's current ratio was 5.15 at the end of fiscal 2025: current assets were 5.15 times current liabilities.